Effective Cough Treatment, Now Digital & Scalable
Clinically validated therapy, powered by AI. Effective, side-effect-free cough treatment available at scale for the first time
Get a Demo
Hyfe DTx: Scaling with Industry Leaders
Hyfe’s AI-powered digital therapeutic for chronic cough is in development in Japan with Kyorin Pharmaceutical. We’re actively seeking partners to bring this breakthrough to more markets.
Read the Press ReleaseChronic cough affects an estimated 9.6%
of people worldwide
Depression
Incontinence
Social Anxiety
Lack of Sleep
A Proven Solution, Now Available to Everyone
Behavioral Cough Suppression Therapy (BCST) has been clinically proven to reduce chronic cough severity in 70% of patients, reducing cough frequency by 41%, making it twice as effective as leading drugs in development.
Traditional access to BCST is severely limited - only ~200 specialists in the U.S. offer it - and Hyfe will scale this gold-standard therapy with an AI-powered digital platform.
Traditional access to BCST is severely limited - only ~200 specialists in the U.S. offer it - and Hyfe will scale this gold-standard therapy with an AI-powered digital platform.
Key Benefits of Hyfe Cough DTx
Validated Efficacy
Three randomized controlled trials confirm BCST’s impact.
Safe & Side Effect-Free
No risks, just results
Accessible Anywhere
Delivered through a user-friendly smartphone app.
At- scale on Japanese Market
In partnership with Kyorin Pharmaceuticals, Hyfe is bringing this solution to the Japanese market.
Tested with coughers globally
Hyfe’s software detects 90% coughs, even in noisy everyday acoustic environments, with just 1.1 false positives / hour.
Objective Monitoring
AI-enabled real-time cough tracking monitors progress and promotes continuous improvement.
Powered by Hyfe's Category Defining Technology
At the heart of Hyfe Cough DTx is our cutting-edge AI cough detection engine, capable of monitoring and analyzing cough patterns. This technology not only empowers patients but also provides data-backed insights for healthcare providers and industry leaders.
Continuous tracking builds real-world evidence for regulatory validation.
Seamless integration with pharma products enhances treatment efficacy by 20-40%.
Real-time data fosters
consumer trust and brand loyalty
The Financial and Healthcare Opportunity:
Chronic cough represents a $17.1 billion market, growing at 6.39% annually.
Patients spend $11 billion annually on OTC remedies with questionable efficacy.
Hyfe's solution reduces healthcare costs by up to $2,500 per patient annually.
For pharma companies,
Hyfe’s DtX offers:
Increased Prescription Adherence: Combination therapy will promote higher compliance, potentially boosting long-term outcomes by 30-50%.
Regulatory & R&D Advantages: Real-world data reduces R&D risks and streamlines market validation.
Market Differentiation: Stand out as an innovator with proven, patient-centric solutions.
Recurring Revenue: Chronic coughers require ongoing care, making BCST a renewable therapy.
Cost Savings: Proven outcomes lower marketing and patient acquisition costs by 15-25%
For consumer wellness brands, Hyfe’s Cough Management Tools drive:
The Financial and Healthcare Opportunity
Prescription & Reimbursement
Unlike many digital therapeutics (DTx) apps, our built-in measurement capabilities make it easier to demonstrate therapeutic efficacy, supporting reimbursement and physician adoption.
Direct-to-Consumer
OTC brands could bundle it with their cough syrups to offer a more complete solution. Alternatively, major pharmacy chains could integrate it into their primary care services.
Employee Wellness Plans
Chronic coughers often drive up healthcare utilization without effective treatment. Employers and insurers could offer our solution as part of a wellness initiative to reduce costs and improve long-term outcomes.
Supporting Providers, Empowering Patients
Chronic coughers describe their journey as "depressing," "frustrating," and "endless."
Hyfe addresses this pain with:
Hyfe addresses this pain with:
Engaging Coaching
Audio-visual BCST guides patients through recovery
Data-Driven Validation
Objective cough monitoring builds confidence in the tool
Comprehensive Support
Beyond symptom relief, Hyfe restores hope and quality of life.
Built on Expertise & Trust
Hyfe's leadership includes Dr. Laurie Slovarp, a globally recognized authority in BCST, ensuring clinical rigor at every step. Backed by partnerships with healthcare leaders, Hyfe combines scientific credibility with technological excellence to redefine chronic cough care.
Partner with Hyfe to Redefine
Chronic Cough Care
Hyfe Cough DTx is a strategic opportunity to lead in digital therapeutics. We invite pharma and consumer wellness leaders to join us in reshaping the landscape of chronic cough management.
Co-Development Opportunities: Bring innovative therapies to market faster.
Licensing & Distribution Models: Scale Hyfe’s proven solution globally.
Revenue Sharing: Tap into the high-growth DTx market.